# Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

> **NCT05702879** · — · UNKNOWN · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 240 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Ozanimod
- **DRUG:** TNF Inhibitor
- **DRUG:** Steroids
- **DRUG:** Vedolizumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT05702879
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-06
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702879, "Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05702879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*